

Asthma and COPD and COVID19 - Letter from the Chief Medical Officer for Scotland to “Very High Risk Groups”.

We are aware that a letter has been sent out to some patients identified by Scottish Government as being in “Very High Groups”. A copy of this letter will be on our website soon. The letter states that your GP will contact you to discuss the letter. However, the list of patients was compiled centrally and has not yet been shared with the practice. As soon as we have the list of patients who have been sent a letter, we will start making contact, as workload allows.

One area that seems to have caused some confusion is the definition of severe asthma and severe COPD which identifies a patient as being in the very high risk group. This definition is quite complicated and we have tried to simplify this below with information that will cover 99% of our patients in this group.

The following patients have been defined by Scottish Government as being in the “very high risk group”:

Severe Asthma

Patients who have been prescribed any medicine for asthma for at least 4 of the 6 months (July to December 2019) **AND** have also been prescribed oral Prednisolone for at least 4 of the 6 months (July to December 2019).

Severe COPD

Patients who have been prescribed Roflumilast in the recent past

OR

Patients on one of the following inhaler combinations:

1. Trelegy Ellipta **OR** Trimbrow
2. A steroid inhaler eg. Clenil **AND** one of the following inhalers
 - Anoro Ellipta
 - Ultibro Breezhaler
 - Spiolto Respimat
 - Duaklir Genuair
3. Fostair **OR** Seretide **AND** one of the following inhalers:
 - Incruse Ellipta
 - Seebri Breezhaler
 - Spiriva Respimat/handihaler
 - Eklira Genuair